4 completed. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
Follow Biothrax: new trials by email Literature Review of Biothrax trials Research Report on Biothrax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults BW-1010: 50 µg - sprayer - IN, BW-1010: 50 µg - pipette - IN, BW-1010: 100 µg - sprayer - IN - Anthrax | Phase 1 | Completed | BlueWillow Biologics | 84 | 2020-01-08 | 2022-05-18 |
| NasoShield Study of Safety and Immunogenicity NasoShield, BioThrax, Placebo - Healthy Volunteers | Phase 1 | Completed | Altimmune, Inc. | 145 | 2018-01-18 | 2025-06-24 |
| A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines AVA, Ad4-PA-1, Ad4-PA-GPI-1 - Anthrax Infection | Phase 1 | Completed | Emergent BioSolutions | 120 | 2013-11-01 | 2024-03-18 |
| Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults BioThrax, AV7909 Formulation 1, AV7909 Formulation 2 - Bacillus Anthracis (Anthrax) Infection | Phase 1 | Completed | Emergent BioSolutions | 105 | 2010-12-01 | 2024-03-18 |
Anthrax (4) · Infections (1)
Emergent BioSolutions (2) · Altimmune, Inc. (1) · BlueWillow Biologics (1)
United States (4)
Edward Bernton, MD (1) · Emanuel DeNoia, MD (1) · Jakub Simon, MD (1) · Marc Gurwith, MD (1) · Mo Elsafy, MD, MSc (1)